NICE endorses alitretinoin use

Patients with severe chronic hand eczema who have run out of treatment options can now be considered for treatment with alitretinoin (Toctino), according to new guidance issued by NICE.

Alitretinoin, an orally administered retinoid, is recommended for adults whose disease has not responded to potent topical corticosteroids. Eligible patients must also have a dermatology life quality index (DLQI) score of 15 or more.

Treatment with alitretinoin should be stopped:

  • when an adequate response (hands clear or almost clear) is achieved.
  • if eczema remains severe after 12 weeks.
  • if an adequate response is not achieved by 24 weeks.

Disease is considered ‘severe' if defined as such by the physician's global assessment (PGA).

Only physicians who are experienced in both the management of severe chronic hand eczema and the use of systemic retinoids should start and monitor treatment with alitretinoin.

View Toctino drug record

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Drug shortages - live tracker

Added: fludroxycortide, levofloxacin, Noriday, Ongentys...

Vaping still safer than smoking, say health bosses after report of severe lung injury
Free online vestibular rehabilitation tool 'highly effective' for vertigo symptoms

Free online vestibular rehabilitation tool 'highly effective' for vertigo symptoms

GPs should consider online vestibular rehabilitation...

Thiazides better than ACE inhibitors as first-line antihypertensives, large-scale analysis suggests